{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:53:31Z","timestamp":1787500411661,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Henan Province Science and Technology Project","award":["182102311245"],"award-info":[{"award-number":["182102311245"]}]},{"name":"Henan Province Science and Technology Project","award":["182102310484"],"award-info":[{"award-number":["182102310484"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been linked to tumor progression in many types of cancer. The role of FGFR3 in melanoma remains unclear. In this study, we aimed to uncover the role of FGFR3 in the growth and metastasis of melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FGFR3 knockdown and overexpression strategies were employed to investigate the effects of FGFR3 on colony formation, cell apoptosis, proliferation, migration, and in vitro invasion, along with the growth and metastasis of melanoma in a xenografts mouse model. The protein expression levels of extracellular signal-regulated kinase (ERK), protein kinase B (AKT), epidermal growth factor receptor (EGFR), and epithelial-mesenchymal transition (EMT) markers were determined by Western blot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mRNA expression of FGFR3 was higher in melanoma tissues than normal healthy tissues. FGFR3 expression in cutaneous malignant melanoma (CMM) tissues was positively correlated with the Breslow thickness and lymph node metastasis. In A357 cells, knockdown of the\n                      <jats:italic>FGFR3<\/jats:italic>\n                      gene decreased the colony formation ability, cell proliferation, invasion, and migration, but increased the caspase 3 activity and the apoptosis rate; overexpression of FGFR3 increased the colony formation ability, cell proliferation, invasion, and migration, but decreased the caspase 3 activity and apoptosis rates. FGFR3 knockdown also upregulated E-cadherin, downregulated N-cadherin and vimentin, and decreased the phosphorylation levels of ERK, AKT, and EGFR. In the MCC xenografts mice, knockdown of FGFR3 decreased tumor growth and metastasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FGFR3, which is highly expressed in CMM tissues, is correlated with increased Breslow thickness and lymph node metastasis. FGFR3 promotes melanoma growth, metastasis, and EMT behaviors, likely by affecting the phosphorylation levels of ERK, AKT, and EGFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6161-8","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T09:09:37Z","timestamp":1571216977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR"],"prefix":"10.1186","volume":"19","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"6161_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1586\/era.10.170","volume":"10","author":"E Erdei","year":"2010","unstructured":"Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10:1811\u201323.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6161_CR2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5:1701\u201352.","journal-title":"Oncotarget."},{"key":"6161_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cytogfr.2005.01.008","volume":"16","author":"M Mohammadi","year":"2005","unstructured":"Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16:107\u201337.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6161_CR4","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684\u201394.","journal-title":"Clin Cancer Res"},{"key":"6161_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0968-0004(97)01170-5","volume":"23","author":"D Burke","year":"1998","unstructured":"Burke D, Wilkes D, Blundell TL, Malcolm S. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci. 1998;23:59\u201362.","journal-title":"Trends Biochem Sci"},{"key":"6161_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","volume":"26","author":"LH Gallo","year":"2015","unstructured":"Gallo LH, Nelson KN, Meyer AN, Donoghue DJ. Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 2015;26:425\u201349.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6161_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cjp2.51","volume":"2","author":"WS Theelen","year":"2016","unstructured":"Theelen WS, Mittempergher L, Willems SM, Bosma AJ, Peters DD, van der Noort V, et al. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer. J Pathol Clin Res. 2016;2:223\u201333.","journal-title":"J Pathol Clin Res"},{"key":"6161_CR8","doi-asserted-by":"publisher","first-page":"e86470","DOI":"10.1371\/journal.pone.0086470","volume":"9","author":"L Salazar","year":"2014","unstructured":"Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, et al. Fibroblast growth factor receptor 3 interacts with and activates TGFbeta-activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple myeloma and bladder cancer. PLoS One. 2014;9:e86470.","journal-title":"PLoS One"},{"key":"6161_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cam4.595","volume":"5","author":"K Koole","year":"2016","unstructured":"Koole K, van Kempen PM, Swartz JE, Peeters T, van Diest PJ, Koole R, et al. Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2016;5:275\u201384.","journal-title":"Cancer Med"},{"key":"6161_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213:91\u20138.","journal-title":"J Pathol"},{"key":"6161_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","volume":"43","author":"K Freier","year":"2007","unstructured":"Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007;43:60\u20136.","journal-title":"Oral Oncol"},{"key":"6161_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm0897-887","volume":"3","author":"Y Wang","year":"1997","unstructured":"Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997;3:887\u201393.","journal-title":"Nat Med"},{"key":"6161_CR13","doi-asserted-by":"publisher","first-page":"24011","DOI":"10.3390\/ijms161024011","volume":"16","author":"GW Yang","year":"2015","unstructured":"Yang GW, Jiang JS, Lu WQ. Ferulic acid exerts anti-Angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis. Int J Mol Sci. 2015;16:24011\u201331.","journal-title":"Int J Mol Sci"},{"key":"6161_CR14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/sj.emboj.7601583","volume":"26","author":"R Grose","year":"2007","unstructured":"Grose R, Fantl V, Werner S, Chioni AM, Jarosz M, Rudling R, et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007;26:1268\u201378.","journal-title":"EMBO J"},{"key":"6161_CR15","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.2147\/OTT.S136677","volume":"10","author":"Y Wang","year":"2017","unstructured":"Wang Y, Bao X, Zhang Z, Sun Y, Zhou X. FGF2 promotes metastasis of uveal melanoma cells via store-operated calcium entry. Onco Targets Ther. 2017;10:5317\u201328.","journal-title":"Onco Targets Ther"},{"key":"6161_CR16","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1172\/JCI28163","volume":"116","author":"C Hafner","year":"2006","unstructured":"Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006;116:2201\u20137.","journal-title":"J Clin Invest"},{"key":"6161_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.23838\/pfm.2018.00044","volume":"2","author":"J Lee","year":"2018","unstructured":"Lee J, Lee J, Hong SD, Jang K-T, Lee SJ, Lee J, et al. FGFR3-TACC3: a novel gene fusion in malignant melanoma. Precision Future Med. 2018;2:71\u20135.","journal-title":"Precision Future Med"},{"key":"6161_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","volume":"25","author":"MA Knowles","year":"2007","unstructured":"Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25:581\u201393.","journal-title":"World J Urol"},{"key":"6161_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.07178","volume":"10","author":"K Junker","year":"2008","unstructured":"Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10:1\u20137.","journal-title":"Neoplasia."},{"key":"6161_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11934-008-0011-6","volume":"9","author":"PC Black","year":"2008","unstructured":"Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008;9:55\u201361.","journal-title":"Curr Urol Rep"},{"key":"6161_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2003-04-1204","volume":"102","author":"ON Onwuazor","year":"2003","unstructured":"Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 2003;102:772\u20133.","journal-title":"Blood."},{"key":"6161_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00062752-200207000-00005","volume":"9","author":"M Chesi","year":"2002","unstructured":"Chesi M, Bergsagel PL, Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol. 2002;9:288\u201393.","journal-title":"Curr Opin Hematol"},{"key":"6161_CR23","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/sj.bjc.6603181","volume":"94","author":"S Streit","year":"2006","unstructured":"Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer. 2006;94:1879\u201386.","journal-title":"Br J Cancer"},{"key":"6161_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6161_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0889-8588(02)00055-2","volume":"16","author":"J Baselga","year":"2002","unstructured":"Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am. 2002;16:1041\u201363.","journal-title":"Hematol Oncol Clin North Am"},{"key":"6161_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2013.01.013","volume":"332","author":"GH Ha","year":"2013","unstructured":"Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K\/Akt and ERK signaling pathways. Cancer Lett. 2013;332:63\u201373.","journal-title":"Cancer Lett"},{"key":"6161_CR27","volume-title":"Immunohistology in diagnostic pathology","author":"JC Jennette","year":"1989","unstructured":"Jennette JC. Immunohistology in diagnostic pathology. Boca Raton: CRC Press Inc.; 1989."},{"key":"6161_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00008390-199708000-00004","volume":"7","author":"NU Ahmed","year":"1997","unstructured":"Ahmed NU, Ueda M, Ito A, Ohashi A, Funasaka Y, Ichihashi M. Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res. 1997;7:299\u2013305.","journal-title":"Melanoma Res"},{"key":"6161_CR29","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","volume":"3","author":"MT Herrera-Abreu","year":"2013","unstructured":"Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013;3:1058\u201371.","journal-title":"Cancer Discov"},{"key":"6161_CR30","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1541-7786.MCR-10-0568","volume":"9","author":"D Yao","year":"2011","unstructured":"Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 2011;9:1608\u201320.","journal-title":"Mol Cancer Res"},{"key":"6161_CR31","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1038\/onc.2008.343","volume":"27","author":"A Jeanes","year":"2008","unstructured":"Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27:6920\u20139.","journal-title":"Oncogene."},{"key":"6161_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2010.04.016","volume":"184","author":"RT Bryan","year":"2010","unstructured":"Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010;184:423\u201331.","journal-title":"J Urol"},{"key":"6161_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6161_CR34","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.4161\/cc.9.12.12050","volume":"9","author":"J Fuxe","year":"2010","unstructured":"Fuxe J, Vincent T. Garcia de Herreros a. transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363\u201374.","journal-title":"Cell Cycle"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6161-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6161-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6161-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T19:18:28Z","timestamp":1602703108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6161-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6161"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6161-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Henan Provincial People\u2019s Hospital Ethics Committee. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study. All mice were handled in accordance with the Animal Care and Use Guidelines of Zhengzhou University under a protocol approved by the Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"963"}}